Explicit|23|41|134..136|0,1,1,1,1,1,1,5,0|as|||as|||Contingency.Cause.Reason||||Wr|Comm|Null|Null||||84..132|0,0;0,1,0;0,1,1,0;0,1,1,1,0;0,1,1,1,1,0;0,1,1,1,1,1,0;0,1,1,1,1,1,1,0;0,1,1,1,1,1,1,1;0,1,1,1,1,1,1,2;0,1,1,1,1,1,1,3;0,1,1,1,1,1,1,4;0,2|to have moved ahead briskly in the third quarter|Inh|Null|Null|Null||||137..211|0,1,1,1,1,1,1,5,1|companies with newer, big-selling prescription drugs fared especially well|Inh|Null|Null|Null|||||||||
Explicit|23|41|1307..1312|7,0,0|While|||while|||Comparison.Contrast||||Wr|Comm|Null|Null||||1337..1499|7,3,1|Neil Sweig, an analyst with Prudential Bache, said that the rate of growth will "look especially good as compared to other companies if the economy turns downward|Ot|Comm|Null|Null|1337..1387|7,1;7,2;7,3,0;7,4;7,5|Neil Sweig, an analyst with Prudential Bache, said|1313..1335|7,0,1|that's not spectacular|Inh|Null|Null|Null|||||||||
Explicit|23|41|1470..1472|7,3,1,1,1,2,2,0|if|||if|||Contingency.Condition.Hypothetical||||Ot|Comm|Null|Null|1337..1387|7,1;7,2;7,3,0;7,4;7,5|Neil Sweig, an analyst with Prudential Bache, said|1393..1469|7,3,1,0;7,3,1,1,0;7,3,1,1,1,0;7,3,1,1,1,1;7,3,1,1,1,2,0;7,3,1,1,1,2,1|the rate of growth will "look especially good as compared to other companies|Inh|Null|Null|Null||||1473..1499|7,3,1,1,1,2,2,1|the economy turns downward|Inh|Null|Null|Null|||||||||
Explicit|23|41|1814..1825|9,0,1,1,0;9,0,1,1,1|even though|||though|||Comparison.Concession.Expectation||||Ot|Comm|Null|Null|1923..1937|9,1;9,2;9,3;9,4|Mr. Sweig said|1799..1813|9,0,0;9,0,1,0|Profit climbed|Inh|Null|Null|Null||||1826..1921|9,0,1,1,2|Merck's sales were reduced by "one to three percentage points" as a result of the strong dollar|Inh|Null|Null|Null|||||||||
Explicit|23|41|3726..3741|25,1,1,1,1,1,0;25,1,1,1,1,1,1|largely because|||because|||Contingency.Cause.Reason||||Ot|Comm|Null|Null|3557..3590|25,0;25,1,0;25,2;25,3|Mr. Riccardo of Bear Stearns said|3596..3725|25,1,1,0;25,1,1,1,0;25,1,1,1,1,0|Schering-Plough Corp. 's expected profit rise of about 18% to 20%, and Bristol-Meyers's expected profit increase of about 13% are|Inh|Null|Null|Null||||3743..3782|25,1,1,1,1,1,3|those companies are really managed well|Inh|Null|Null|Null|||||||||
Explicit|23|41|3843..3848|26,1,3,0|while|||while|||Comparison.Contrast.Juxtaposition||||Wr|Comm|Null|Null||||3785..3841|26,0;26,1,0;26,1,1;26,1,2;26,2|ScheringPlough earned $94.4 million, or 84 cents a share|Inh|Null|Null|Null||||3849..3940|26,1,3,1|Bristol-Myers earned $232.3 million, or 81 cents a share, in the like period a year earlier|Inh|Null|Null|Null|||||||||
Explicit|23|41|4363..4365|29,3,1,1,1,2,0|as|||as|||Contingency.Pragmatic cause.Justification||||Ot|Comm|Null|Null|4278..4291|29,1;29,2;29,3,0;29,4|analysts said|4292..4361|29,0;29,1;29,3,1,0;29,3,1,1,0;29,3,1,1,1,0;29,3,1,1,1,1;29,4|Pfizer's recent string of lackluster quarterly performances continued|Inh|Null|Null|Null||||4366..4426|29,3,1,1,1,2,1|earnings in the quarter were expected to decline by about 5%|Inh|Null|Null|Null|||||||||
Explicit|23|41|5288..5291|37,0,4|but|||but|||Comparison.Contrast||||Ot|Comm|Null|Null|5414..5427|37,1;37,2;37,3;37,4|analysts said|5185..5286|37,0,0;37,0,1;37,0,2;37,0,3|Also, the company's hair-growing drug, Rogaine, is selling well -- at about $125 million for the year|Inh|Null|Null|Null||||5292..5412|37,0,5|the company's profit from the drug has been reduced by Upjohn's expensive print and television campaigns for advertising|Inh|Null|Null|Null|||||||||
Explicit|23|41|250..257|1,2|however|||however|||Comparison.Contrast||||Wr|Comm|Null|Null||||9..211|0,0;0,1,0;0,1,1,0;0,1,1,1,0;0,1,1,1,1,0;0,1,1,1,1,1,0;0,1,1,1,1,1,1,0;0,1,1,1,1,1,1,1;0,1,1,1,1,1,1,2;0,1,1,1,1,1,1,3;0,1,1,1,1,1,1,4;0,2|Earnings for most of the nation's major pharmaceutical makers are believed to have moved ahead briskly in the third quarter, as companies with newer, big-selling prescription drugs fared especially well|Inh|Null|Null|Null||||215..248;259..385|1,0;1,1;1,3;1,4;1,5;1,6|For the third consecutive quarter most of the companies' revenues were battered by adverse foreign-currency translations as a result of the strong dollar abroad|Inh|Null|Null|Null|||||||||
Explicit|23|41|1057..1068|5,0,0|As a result|||as a result|||Contingency.Cause.Result||||Ot|Comm|Null|Null|1166..1183|5,1;5,2;5,3;5,4;5,5|Mr. Riccardo said|807..1055|4,1,1,0;4,1,1,1,0;4,1,1,1,1;4,1,1,1,2,0;4,1,1,1,2,1,0;4,1,1,1,2,1,1;4,1,1,1,2,1,2,0;4,1,1,1,2,1,2,1,0;4,1,1,1,2,1,2,1,1|Joseph Riccardo, an analyst with Bear, Stearns & Co., said that over the past few years most drug makers have shed their slow-growing businesses and instituted other cost savings, such as consolidating manufacturing plants and administrative staffs|Ot|Comm|Null|Null|807..865|4,0;4,1,0;4,2|Joseph Riccardo, an analyst with Bear, Stearns & Co., said|1071..1183|5,0,1;5,0,2;5,0,3;5,0,4|major new products are having significant impact, even on a company with very large revenues," Mr. Riccardo said|Inh|Null|Null|Null||||987..1055|4,1,1,1,2,1,2,1,2|such as consolidating manufacturing plants and administrative staffs|||
Explicit|23|41|2602..2606|17,1,1,1,1,1,1|also|||also|||Expansion.Conjunction||||Wr|Comm|Null|Null||||2499..2538|12,1,1|In Indianapolis, Lilly declined comment|Ot|Comm|Null|Null|2110..2124|12,0;12,1,0;12,2|Mr. Sweig said|2542..2601;2607..2714|17,1,1,0;17,1,1,1,0;17,1,1,1,1,0;17,1,1,1,1,1,0;17,1,1,1,1,1,2|Several analysts said they expected Warner-Lambert's profit to increase by more than 20% from $87.7 million, or $1.25 a share, it reported in the like period last year|Ot|Comm|Null|Null|2542..2563|17,0;17,1,0;17,2|Several analysts said||||||
Explicit|23|41|4267..4276|29,0|Meanwhile|||meanwhile|||Comparison.Contrast.Juxtaposition||||Wr|Comm|Null|Null||||4133..4263|8,1,1,0;8,1,1,1,0;8,1,1,1,1,0;8,1,1,1,1,1;8,1,1,1,1,2;12,1,1,1,1,1,0;12,1,1,1,1,1,1,0;12,1,1,1,1,1,1,1,0;12,1,1,1,1,1,1,1,1;12,1,1,1,1,1,1,1,2;17,1,1,1,1,1;22,2,1,2;25,1,1,0;25,1,1,1,0;25,1,1,1,0,2;25,1,1,1,0,3|The company expects to achieve the 20% increase in full-year earnings per share, as it projected in the spring, the spokesman said|Ot|Ctrl|Null|Null|3203..3224;3557..3590|22,2,0;22,2,1,0;22,2,1,1;25,0;25,1,0;25,2;25,3|estimated by analysts Mr. Riccardo of Bear Stearns said|4278..4426|29,3,1,1,1,2,1,1,1,1|analysts said Pfizer's recent string of lackluster quarterly performances continued, as earnings in the quarter were expected to decline by about 5%|Ot|Ctrl|Null|Null|4366..4403|29,3,1,1,1,2,1,0;29,3,1,1,1,2,1,1,0;29,3,1,1,1,2,1,1,1,0|earnings in the quarter were expected||||||
Explicit|23|41|5185..5189|37,0,0|Also|||also|||Expansion.Conjunction||||Wr|Comm|Null|Null||||5007..5183|36|Sales of both drugs have been hurt by new state laws restricting the prescriptions of certain tranquilizing medicines and adverse publicity about the excessive use of the drugs|Inh|Null|Null|Null||||5191..5427|37,0,1;37,0,2;37,0,3;37,0,4;37,0,5|the company's hair-growing drug, Rogaine, is selling well -- at about $125 million for the year, but the company's profit from the drug has been reduced by Upjohn's expensive print and television campaigns for advertising, analysts said|Ot|Comm|Null|Null|5414..5427|37,1;37,2;37,3;37,4|analysts said||||||
